Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia만성 림프구성 백혈병 환자에서 BNT162b mRNA COVID-19 백신의 안전성 및 효능Article Published on 2022-03-012022-09-11 Journal: Haematologica [Category] MERS, SARS, 진단, 치료기술, [키워드] a BTK inhibitor adverse event age Analysis anti-CD20 antibodies antibody Antibody Response BCl2 BNT162b BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine BTK inhibitor CD20 chronic lymphocytic leukemia CLL CLL patients Cohort Combination Concordance COVID-19 vaccine develop disease Efficacy eligible hemoglobin humoral IgA IgG IgM immune response individuals introduced investigated leukemia Lymphocytic leukemia monotherapy mRNA Neutralizing antibodies neutralizing antibody nine parameter Patient patients patients treated positive predict response response to vaccination Safe Safety second dose serological response Spike protein the vaccine treated treated patients Treatment treatment with anti-CD20 Vaccine [DOI] 10.3324/haematol.2021.279196 PMC 바로가기 [Article Type] Article
Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic LeukemiaCase Report Published on 2022-02-042022-10-31 Journal: Case Reports in Hematology [Category] COVID-19, [키워드] antibody B-cells boost CD4 CD4 T-cell CD8 T-cell chronic CLL CLL patients COVID-19 COVID-19 vaccination dose effective followed by Heterologous immune immune responses immunogenicity individual individuals initial leukemia memory memory B-cell mRNA mRNA vaccination mRNA vaccine Patient Pfizer poorly immunogenic remained respond SARS-CoV-2 seroconvert seroconverted subject Treatment Two subjects vaccination were assessed while [DOI] 10.1155/2022/6831640 PMC 바로가기 [Article Type] Case Report
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients만성 림프구성 백혈병 환자의 코로나19: 연속 환자에서 13개월 동안 임상 결과 및 B 세포 및 T 세포 면역Article Published on 2022-02-012022-09-11 Journal: Leukemia [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단, 치료기술, [키워드] Admission admitted to ICU age Analysis anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody BMI Clinical outcome CLL CLL patient CLL patients consecutive patient death detectable eight ELISPOT Gender Hospitalization hospitalizations Hospitalized ICU admission Immunity immunological indolent median age MOST Multivariate analysis Neutralizing antibodies neutralizing antibody occurred outcome pandemic Patient patients reduced remained risk factor robust Saliva Seroconversion severe COVID-19 subgroup subgroups T cell T-cell T-cell immunity T-cells therapy [DOI] 10.1038/s41375-021-01424-w PMC 바로가기 [Article Type] Article
Chronic Lymphocytic Leukemia in the SARS-CoV-2 PandemicSARS-CoV-2 유행병의 만성 림프구성 백혈병Review Published on 2022-02-012022-09-12 Journal: Current oncology reports [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] antagonists anti-CD20 anti-SARS-CoV-2 anti-SARS-CoV-2 immune responses antibody BTK BTK inhibitors cancers Case fatality rate caused CFR CFRs chronic chronic lymphocytic leukemia Clinical course CLL CLL patient CLL patients Comorbidity contribute controls COVID-19 COVID-19 incidence COVID-19 vaccine decrease deficiency Efficacy elevated form General population greater healthy Hospitalization immune immune response immune system Immunosuppression IMPROVE incidence Infection leukemia lymphoproliferative disease malignancies malignancy monoclonal antibodies older patients outbreak outcome Oxygen therapy pandemic Patient patients with comorbidity Prevalence recent reduced reported response risk of death SARS-CoV-2 SARS-CoV-2 positivity severe infections significantly significantly higher Spike-specific antibody the disease the median the SARS-CoV-2 therapy Treatment vaccination Vaccine Vaccines [DOI] 10.1007/s11912-022-01198-z PMC 바로가기 [Article Type] Review
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemiaB 세포 만성 림프구성 백혈병 백신 접종 환자에서 SARS-CoV-2 델타 변이체 중화 장애Research Published on 2022-01-092022-09-10 Journal: Journal of Hematology & Oncology [Category] 변종, 진단, [키워드] Adenovirus adenovirus-based antibody Antibody Response Antibody responses B cell BTKi therapy CD20 Chronic lymphocytic leukaemia CLL CLL patient CLL patients control group controls COVID COVID-19 vaccination delta variant dominant dual failure functional Gender groups healthy controls healthy donor healthy donors immune protection Immune suppression Immunotherapy Impaired impaired antibody response impaired antibody responses indicate Leukaemia magnitude mRNA neutralisation Patient patient cohort post treatment Post-vaccine Predictive prophylactic antibiotics reduced respond responders responses Result risk SARS-CoV-2 SARS-CoV-2 delta SARS-COV-2 infection sera Seroconversion serum spike-specific antibody response stability supplementary material the SARS-CoV-2 titre titres Treatment vaccination Vaccine vaccine platform variant [DOI] 10.1186/s13045-021-01219-7 PMC 바로가기 [Article Type] Research
Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-UpOncology Published on 2020-07-032022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] accumulate acute respiratory syndrome antiviral therapy B cell B cells B-cell Blood Cell chronic lymphocytic leukemia circulating clearance Clinical characteristics CLL CLL patients clone Cluster combination regimen coronavirus coronavirus disease-2019 COVID COVID-19 criteria cytoplasm deficiency demonstrated diagnosed with COVID-19 distribution early stage effective etiology female flow cytometry Follow-up help Hematological malignancy High-dose highest home quarantine hospital human-to-human transmission humoral immune response Humoral immunity IgG antibody IgM and IgG immune Ineffective ineffective clearance infected with COVID-19 Infection Intravenous immunoglobulin Isolation laboratory result leukemia Lung injury lymphocyte lymphocytosis outbreak Patient plasma prevent disease progression progeny progression reported response severe disease severe pneumonia suffered T lymphocytes therapy Viral load virus infection Wuhan, China [DOI] 10.3389/fonc.2020.01272 PMC 바로가기 [Article Type] Oncology